

HOMBURGER ADVISES ADC THERAPEUTICS IN ITS IPO ON THE NEW YORK STOCK EXCHANGE

Posted on 19 May 2020



Category: [Banking & Finance](#)

Tags: [Benjamin Leisinger](#), [Daniel Häusermann](#), [Dieter Gericke](#), [Estelle Piccard](#), [Ex-Featured](#), [Homburger](#), [Manuel Dubach](#), [Oliver Kneubühl](#), [Olivier Baum](#), [Reto Heuberger](#), [Stefan Oesterhelt](#)



On May 15, 2020, **ADC Therapeutics** listed its shares on the New York Stock Exchange (ticker symbol ADCT). ADCT is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of antibody drug conjugates. Through its IPO, at Usd 19 per share, ADCT raises gross proceeds of USD 267 m including greenshoe. At market close on the first day of trading, ADCT had a market capitalization of USD 2.1 bn. ADCT is the first Swiss company to go public in 2020.

The team

Homburger advises ADC Therapeutics. The team is led by partner **Dieter Gericke** (corporate and m&a - pictured) and includes partners **Reto Heuberger** and **Stefan Oesterhelt** (both tax), **Benjamin Leisinger** (banking and finance), as well as associates **Daniel Häusermann**, **Estelle Piccard** (both corporate and m&a), **Olivier Baum** (banking and finance), **Manuel Dubach** (tax) and junior associate **Oliver Kneubühl** (corporate and m&a).